Ipratropiumbromide 1a Pharma

Ipratropium Bromide, the active ingredient in Ipratropiumbromide 1a Pharma, is an anticholinergic presented as a bronchodilator for inhalation use. It treats chronic obstructive pulmonary disease (COPD) and asthma by competitively blocking muscarinic receptors in airway smooth muscle, leading to bronchodilation and improved airflow. The product complies with EU pharmaceutical standards and is supplied in a ready‑to‑use inhalation formulation.

GNH USA supplies Ipratropiumbromide 1a Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium Bromide is used as a bronchodilator in the management of obstructive airway diseases.

- Chronic obstructive pulmonary disease (COPD): improves airflow and reduces the frequency of exacerbations. - Asthma: provides additional bronchodilation when used with other maintenance therapies. - Chronic bronchitis: helps decrease sputum production and dyspnea associated with airway obstruction.

Ipratropium Bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Cough: transient irritation of the airway. - Dry mouth: reduced salivary secretion. - Throat irritation: burning or soreness after inhalation. - Headache: mild and often transient. - Dizziness: occasional light‑headedness. - Nasal irritation: discomfort in the nasal passages.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Allergic reactions: rash, itching, or hives. - Angioedema: swelling of face, lips, or tongue. - Severe cough: persistent and distressing. - Chest tightness: feeling of constriction in the chest. - Respiratory distress: difficulty breathing requiring medical attention.

Before prescribing Ipratropium Bromide, clinicians should consider several safety measures.

- Renal function: assess in patients with severe renal impairment. - Glaucoma: use with caution in narrow‑angle glaucoma patients. - Urinary retention: avoid in individuals with a history of urinary outflow obstruction. - Respiratory status: monitor for worsening symptoms or paradoxical bronchospasm. - Concomitant anticholinergics: limit combined use to reduce anticholinergic load. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Ipratropium Bromide can interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other inhaled anticholinergics (e.g., tiotropium): may increase anticholinergic side effects. - Ophthalmic anticholinergics in glaucoma patients: risk of increased intra‑ocular pressure. - Drugs causing urinary retention (e.g., antihistamines): may exacerbate retention.

Moderate Interactions (Monitor Closely):\n- Beta‑2 agonists: additive bronchodilation may increase heart rate. - Theophylline: heightened risk of tremor or tachycardia. - ACE inhibitors: overlapping cough side effects may complicate assessment.